



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020**

Rs. in Million

Sl. No.	Particulars	3 Months ended September 30, 2020	Preceding 3 Months ended June 30, 2020	Corresponding 3 Months ended in the previous year September 30, 2019	Year to date figures for the current period ended September 30, 2020	Year to date figures for the previous period ended September 30, 2019	Previous year ended March 31, 2020
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
	Continuing operations						
I	Revenue from operations	7,935.58	7,817.97	7,150.91	15,753.55	14,008.90	27,519.71
II	Other income	128.71	123.05	129.87	251.76	232.40	531.13
III	Total income (I + II)	8,064.29	7,941.02	7,280.78	16,005.31	14,241.30	28,050.84
IV	Expenses						
	(a) Cost of materials consumed	3,215.32	2,766.94	2,579.89	5,982.26	5,671.50	10,203.49
	(b) Purchases of stock-in-trade	619.67	440.39	335.37	1,060.06	717.70	1,469.43
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(750.51)	(184.78)	73.70	(935.29)	(241.70)	(448.11)
	(d) Employee benefits expense	1,383.14	1,297.83	1,097.05	2,680.97	2,068.30	4,425.58
	(e) Finance costs	368.66	369.10	404.20	737.76	757.60	1,557.20
	(f) Depreciation and amortisation expense	527.90	491.32	419.99	1,019.22	848.90	1,737.02
	(g) Other expenses	1,895.87	1,987.48	1,599.00	3,883.35	3,091.10	6,522.00
	(h) Foreign exchange (gain) / loss - net	(48.83)	(38.93)	(10.84)	(87.76)	16.10	188.34
	Total expenses (IV)	7,211.22	7,129.35	6,498.36	14,340.57	12,929.50	25,654.95
V	Profit before exceptional items and tax (III - IV)	853.07	811.67	782.42	1,664.74	1,311.80	2,395.89
VI	Exceptional items - net gain / (loss) (Refer note 8)	131.33	449.18	834.36	580.51	767.90	(776.80)
VII	Profit before tax (V + VI)	984.40	1,260.85	1,616.78	2,245.25	2,079.70	1,619.09
VIII	Share of loss of joint ventures and associates	(301.22)	(209.60)	(212.52)	(510.82)	(390.60)	(1,072.29)
IX	Profit before tax (VII + VIII)	683.18	1,051.25	1,404.26	1,734.43	1,689.10	546.80
X	Tax expense						
	- Current tax	76.73	68.10	160.76	144.83	315.80	280.07
	- Deferred tax	(15.69)	(35.27)	(87.00)	(50.96)	(210.80)	(166.84)
	Total tax expense (X)	61.04	32.83	73.76	93.87	105.00	113.23
XI	Profit after tax from continuing operations (IX - X)	622.14	1,018.42	1,330.50	1,640.56	1,584.10	433.57
XII	Discontinued operations						
	- Profit / (loss) from discontinued operations	-	-	(25.61)	-	(184.20)	(184.16)
	- Gain on disposal of assets / settlement of liabilities attributable to the discontinued operations (net)	147.72	-	114.20	147.72	114.20	122.44
	- Tax expense / (benefit) of discontinued operations	-	-	-	-	65.89	65.89
XIII	Profit/(loss) after tax from discontinued operations	147.72	-	88.59	147.72	(135.89)	(127.61)
XIV	Profit for the period (XI + XIII)	769.86	1,018.42	1,419.09	1,788.28	1,448.21	305.96



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020**

Rs. in Million

Sl. No.	Particulars	3 Months ended September 30, 2020	Preceding 3 Months ended June 30, 2020	Corresponding 3 Months ended in the previous year September 30, 2019	Year to date figures for the current period ended September 30, 2020	Year to date figures for the previous period ended September 30, 2019	Previous year ended March 31, 2020
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
XV	Other comprehensive income						
A	(i) Items that will not be reclassified to statement of profit and loss	(62.66)	186.89	(8.28)	124.23	(88.40)	(147.24)
	(ii) Income tax relating to items that will not be reclassified to statement of profit and loss	11.99	(39.83)	-	(27.84)	-	8.32
B	(i) Items that may be reclassified to statement of profit and loss	(94.11)	283.93	364.22	189.82	58.40	329.80
	(ii) Income tax relating to items that may be reclassified to statement of profit and loss	(61.76)	(59.22)	13.60	(120.98)	21.30	179.82
	Total other comprehensive income for the period (XV)	(206.54)	371.77	369.54	165.23	(8.70)	370.70
XVI	Total comprehensive income for the period (XIV + XV)	563.32	1,390.19	1,788.63	1,953.51	1,439.51	676.66
	Profit for the period attributable to:						
	- Owners of the Company	809.45	1,035.64	1,427.16	1,845.09	1,464.21	363.91
	- Non-controlling interests	(39.59)	(17.22)	(8.07)	(56.81)	(16.00)	(57.95)
		769.86	1,018.42	1,419.09	1,788.28	1,448.21	305.96
	Other comprehensive income for the period						
	- Owners of the Company	(204.22)	371.56	368.92	167.34	(1.60)	378.52
	- Non-controlling interests	(2.32)	0.21	0.62	(2.11)	(7.10)	(7.82)
		(206.54)	371.77	369.54	165.23	(8.70)	370.70
	Total comprehensive income for the period						
	- Owners of the Company	605.23	1,407.20	1,796.08	2,012.43	1,462.61	742.43
	- Non-controlling interests	(41.91)	(17.01)	(7.45)	(58.92)	(23.10)	(65.77)
		563.32	1,390.19	1,788.63	1,953.51	1,439.51	676.66
	Earnings per equity share (face value of Rs. 10/- each) (for continuing operations)						
	(1) Basic (in Rs.)	7.39	11.56	14.95	18.95	18.06	5.68
	(2) Diluted (in Rs.)	7.38	11.56	14.95	18.93	18.06	5.68
	Earnings per equity share (face value of Rs. 10/- each) (for discontinued operations)						
	(1) Basic (in Rs.)	1.64	-	0.99	1.65	(1.71)	(1.62)
	(2) Diluted (in Rs.)	1.65	-	0.99	1.65	(1.71)	(1.62)
	Earnings per equity share (face value of Rs. 10/- each) (for total operations)						
	(1) Basic (in Rs.)	9.03	11.56	15.94	20.60	16.35	4.06
	(2) Diluted (in Rs.)	9.03	11.56	15.94	20.58	16.35	4.06
	See accompanying notes to the Financial Results						



STRIDES PHARMA SCIENCE LIMITED

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020**

CONSOLIDATED BALANCE SHEET

Rs. in Million

	Particulars	As at September 30, 2020	As at March 31, 2020
		UNAUDITED	AUDITED
A	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	10,648.39	10,687.21
	(b) Capital work-in-progress	1,980.61	1,480.55
	(c) Right -of -use assets	2,340.74	2,471.63
	(d) Investment property	704.94	728.02
	(e) Goodwill	4,603.63	4,285.58
	(f) Other Intangible assets	3,579.96	2,814.07
	(g) Intangibles assets under development	2,350.53	2,648.91
	(h) Investment in associates and joint ventures	5,320.57	4,293.97
	(i) Financial assets		
	(i) Investments	132.42	10.38
	(ii) Loans receivable	387.31	389.69
	(iii) Other financial assets	4,882.87	4,174.05
	(j) Deferred tax assets (net)	2,036.80	1,985.75
	(k) Income tax assets (net)	1,424.74	1,333.95
	(l) Other non-current assets	264.33	492.46
	Total non-current assets	40,657.84	37,796.22
II	Current assets		
	(a) Inventories	9,310.74	7,825.39
	(b) Financial assets		
	(i) Investments	1,040.48	1,189.68
	(ii) Trade receivables	10,110.22	9,316.94
	(iii) Cash and cash equivalents	1,288.45	1,822.34
	(iv) Other balances with banks	699.69	548.63
	(v) Loans receivable	18.61	148.31
	(vi) Other financial assets	134.27	71.58
	(c) Other current assets	3,048.31	2,783.24
	Total current assets	25,650.77	23,706.11
	Assets held for sale	15.00	15.00
	Total Assets	66,323.61	61,517.33



STRIDES PHARMA SCIENCE LIMITED

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS

FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020

Rs. in Million

	Particulars	As at	As at
		September 30, 2020	March 31, 2020
		UNAUDITED	AUDITED
B	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	896.26	895.65
	(b) Other equity	25,991.89	24,378.52
	Equity attributable to owners of the Company	26,888.15	25,274.17
	Non- Controlling interests	502.20	672.38
	Total equity	27,390.35	25,946.55
II	Liabilities		
1	Non-current liabilities		
	(a) Financials liabilities		
	(i) Lease liabilities	2,343.87	2,538.33
	(ii) Borrowings	7,192.29	6,039.09
	(iii) Other financial liabilities	818.14	678.43
	(b) Provisions	648.77	639.52
	(c) Deferred tax liabilities (net)	359.48	208.16
	(d) Other non-current liabilities	17.08	18.68
	Total non-current liabilities	11,379.63	10,122.21
2	Current liabilities		
	(a) Financials liabilities		
	(i) Lease liabilities	362.92	190.92
	(ii) Borrowings	12,390.13	12,287.75
	(iii) Trade payables		
	(a) total outstanding dues of micro enterprises and small enterprises	276.95	199.52
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	9,570.68	7,777.96
	(iv) Other financial liabilities	2,518.16	2,646.96
	(b) Provisions	1,281.36	1,255.24
	(c) Current tax liabilities	496.78	383.20
	(d) Other current liabilities	656.65	707.02
	Total current liabilities	27,553.63	25,448.57
	Total Equity and liabilities	66,323.61	61,517.33



STRIDES PHARMA SCIENCE LIMITED
 Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
 Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020

CONSOLIDATED STATEMENT OF CASH FLOW

Sl. No.	Particulars	Rs. In Million		
		For the Current period ended September 30, 2020	For the previous period ended September 30, 2019	For the previous year ended March 31, 2020
		UNAUDITED	UNAUDITED	AUDITED
A.	Cash flow from operating activities			
	Profit / (loss) before tax from:			
	Continuing operations	1,734.43	1,689.10	546.80
	Discontinued operations	147.72	(70.00)	(61.72)
		1,882.15	1,619.10	485.08
	Adjustments for:			
	- Depreciation and amortisation expense	1,019.22	989.81	1,877.91
	- Share of loss of joint ventures and associates	510.82	395.56	1,077.26
	- Loss on sale of property, plant and equipment and other intangible assets (net)	4.13	9.84	53.05
	- Share based compensation expense	4.77	14.04	17.53
	- Unwinding of discount on gross obligations over written put options to NCI	5.59	19.60	9.40
	- Cancellation of gross obligations over written put options to NCI	-	(1,092.94)	(1,092.94)
	- Unwinding of discount on contingent consideration payable	37.44	50.35	53.57
	- Fair valuation of derivative instruments	-	-	3.78
	- Interest expense on borrowings & others	737.76	1,076.90	1,876.45
	- Interest and dividend income	(187.08)	(186.79)	(427.54)
	- Gain on disposal of assets / settlement of liabilities attributable to the discontinued operations (net)	(147.72)	(114.20)	(122.44)
	- Rental income from investment property	(37.86)	(37.34)	(74.61)
	- Liability / provision no longer required written back	(5.53)	-	-
	- Bad debts written off / provision for doubtful trade and other receivables	114.73	20.94	114.74
	- Impairment of goodwill	-	94.89	94.89
	- Restructuring and divestment related expenses	-	99.56	99.56
	- Write down of inventory and other assets	84.83	-	1,131.12
	- Fair valuation gain on acquisition of controlling shares in Fairmed healthcare AG	(25.30)	-	-
	- Net unrealised exchange loss/ (gain)	(764.11)	142.74	583.14
	Operating profit before working capital changes	3,233.84	3,102.06	5,759.95
	Changes in working capital:			
	(Increase) / decrease in trade and other receivables	(805.76)	(1,794.52)	(1,591.07)
	Decrease / (increase) in inventories	(1,404.74)	(173.18)	(1,625.24)
	(Decrease)/ Increase in trade and other payables	469.10	(282.30)	(45.99)
	Net change in working capital	(1,741.40)	(2,250.00)	(3,262.30)
	Cash generated from operations	1,492.44	852.06	2,497.65
	Income taxes paid	(121.98)	(132.96)	(449.78)
	Net cash flow generated from operating activities	1,370.46	719.10	2,047.87
	A			



STRIDES PHARMA SCIENCE LIMITED
Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
 Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020

Sl. No.	Particulars	Rs. In Million		
		For the Current period ended September 30, 2020	For the previous period ended September 30, 2019	For the previous year ended March 31, 2020
		UNAUDITED	UNAUDITED	AUDITED
B.	Cash flow from investing activities			
	Capital expenditure for property, plant and equipment and intangible assets, including capital advance	(1,176.66)	(946.97)	(1,500.02)
	Proceeds from sale of property, plant and equipment and intangible assets	5.39	6.23	36.75
	Purchase of long-term investments including investment in associates	(1,712.64)	(610.33)	(1,101.07)
	Consideration paid towards acquisition of non-controlling interest in subsidiary and business combinations, net of cash acquired	(85.91)	(181.63)	(272.26)
	Proceeds from sale of investment in mutual funds	115.61	1,477.68	1,779.65
	Proceeds from sale of long-term investments including discontinued operations, net of expenses and cash	105.76	12,919.19	12,894.46
	Loan (given) to others	-	(89.40)	(210.69)
	Loan recovered from others	-	250.00	250.00
	Rent deposit received / (given)	-	(12.10)	(12.10)
	Proceeds / (investment) in fixed deposits with maturity of more than 3 months, net	(176.17)	651.45	884.92
	Rental income from investment property	43.11	38.75	80.07
	Interest and dividends received (net of tax on dividend)	51.98	81.29	231.88
	Net cash flow generated from / (utilised) in investing activities	(2,829.53)	13,584.16	13,061.59
	B			
C.	Cash flow from financing activities			
	Proceeds from issue of equity shares	18.12	0.58	4.80
	Proceeds from long-term borrowings	2,879.42	163.34	686.12
	Repayment of long-term borrowings	(1,381.80)	(13,387.69)	(13,740.18)
	Net (decrease) / increase in working capital and short-term borrowings	423.20	(298.93)	(442.07)
	Lease payments	(185.06)	(54.66)	(347.23)
	Dividends paid (net of tax on dividend)	(179.15)	(1,538.92)	(1,538.95)
	Proceeds from issue of shares to minority shareholders	1.67	0.21	0.62
	Dividend paid to minority shareholders	-	(9.49)	(9.49)
	Interest paid on borrowings	(641.01)	(1,023.74)	(1,708.11)
	Net cash (utilised) / generated from financing activities	935.39	(16,149.30)	(17,094.49)
	C			



STRIDES PHARMA SCIENCE LIMITED
Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
 Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.
STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020

Sl. No.	Particulars	Rs. In Million		
		For the Current period ended September 30, 2020	For the previous period ended September 30, 2019	For the previous year ended March 31, 2020
		UNAUDITED	UNAUDITED	AUDITED
	Net decrease in cash and cash equivalents during the year (A+B+C)	(523.68)	(1,846.04)	(1,985.03)
	Cash and cash equivalents at the beginning of the year	1,822.34	3,658.89	3,658.89
	Effect of exchange differences on restatement of foreign currency cash and cash equivalents	(10.21)	(39.50)	148.48
	Cash and cash equivalents at the end of the year*	1,288.45	1,773.35	1,822.34
	* Comprises:			
	Cash on hand	3.10	2.50	2.43
	Balance with banks:			
	- In current accounts	1,190.62	1,344.38	1,467.44
	- In deposit accounts	5.19	270.00	264.06
	- Funds-in-transit	89.54	156.47	88.41
	Total	1,288.45	1,773.35	1,822.34



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020**

Notes:

- These financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on October 29, 2020. The statutory auditors have reviewed the results for the quarter and half year ended September 30, 2020 and have issued an unmodified opinion.
- The Group effective the previous quarter have reported its results in Indian Rupees "Millions" instead of Indian Rupees "Lakhs" till the year ended 31 March 2020. Pursuant to such change, all comparative numbers have been presented in Indian Rupees millions and have been rounded off to two decimal places
- During the previous year, the Group completed the divestment of its Australia business for a consideration of AUD 406 Million (including a deferred consideration of AUD 106 Million) reduced by the bank debt settlement of AUD 22.47 Million. Additionally, the Group has retained global access to IP's of over 140 products and has concurrently entered into a preferred supply agreement with Arrotex. The resulting gain from the disposal of Rs.122 Million in the previous period is accounted under the head "Gain on disposal of assets attributable to the discontinued operations (net)" and is presented as part of discontinued operations. Accordingly, the Group has classified the Australia business operations as discontinued operations. The results of discontinued operations (including discontinued operations of earlier periods) are disclosed in the table below:

Sl. No.	Particulars	Rs. in Million					
		3 Months ended September 30, 2020	Preceding 3 Months ended June 30, 2020	Corresponding 3 Months ended in the previous year September 30, 2019	Year to date figures for the current period ended September 30, 2020	Year to date figures for the previous period ended September 30, 2019	Previous year ended March 31, 2020
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
I	Total Revenue	-	-	-	-	2,305.00	2,304.97
II	Total Expenses	-	-	25.61	-	2,371.00	2,370.99
III	Profit/(loss) before exceptional items and tax (I - II)	-	-	(25.61)	-	(66.00)	(66.02)
IV	Exceptional items	-	-	-	-	(113.19)	(113.17)
V	Profit/(loss) before tax (III + IV)	-	-	(25.61)	-	(179.19)	(179.19)
VI	Share of profit / (loss) of joint ventures and associates	-	-	-	-	(5.01)	(4.97)
VII	Profit/(loss) before tax (V + VI)	-	-	(25.61)	-	(184.20)	(184.16)
VIII	Gain / (loss) on disposals (net)	147.72	-	114.20	147.72	114.20	122.44
IX	Tax expense / (benefit)	-	-	-	-	65.89	65.89
X	Profit/(loss) from discontinued operations (VII+ VIII - IX)	147.72	-	88.59	147.72	(135.89)	(127.61)

- On December 4, 2013, the Company and its wholly owned subsidiary, Strides Pharma Asia Pte Limited ("the Singapore Subsidiary"), completed the sale of investments in Agila Specialties Private Limited and Agila Specialties Global Pte Limited (together, "Agila") to Mylan Laboratories Limited and Mylan Institutional Inc. (together, "Mylan") pursuant to separate agreements, each dated as of February 27, 2013 (the "SPAs"). Under the terms of SPA, the Group is entitled to the benefit of any refund of taxes in respect of any period ending on or before the completion date.

During the current quarter, Mylan has received certain tax refund with respect to the period on or before the completion date, which has been remitted to the Group. The Group has recorded such receipt of Rs. 147.72 million under discontinued operations (Refer Note 4 above)



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020**

- 6 During the previous quarter, the Group gained controlling interest in Fairmed Healthcare AG, Switzerland, thereby making it a subsidiary of the group. Pursuant to the acquisition of controlling interest in Fairmed, in accordance with Ind AS 103 "Business Combinations", the group recorded a gain of Rs. 25.30 Million, being the difference in the fair value of non-controlling interest held and carrying value of equity in Fairmed.
- 7 On March 31, 2020, US Food and Drug Administration (USFDA or the Agency) issued letters to all manufacturers of Ranitidine across dosage forms requesting withdrawal of all prescription(Rx) and over-the-counter (OTC) ranitidine drugs from the market immediately. This step was based on their ongoing investigation of the N-Nitrosodimethylamine (NDMA) impurity in ranitidine medications. As a result, effective 1 April 2020, the Group has ceased further distribution of the product and is currently in the process of withdrawing the product from the market. During the period, the group has received a significant portion of the product returns from its customers, with the corresponding value being deducted by its customers on their payments to the group. The Company believes that the existing provisions for sales return for Ranitidine will be sufficient to settle the balance claims from its customers.

8 Exceptional Item gain/ (loss) (net):

Rs. in Million

Particulars	3 Months ended September 30, 2020	Preceding 3 Months ended June 30, 2020	Corresponding 3 Months ended in the previous year September 30, 2019	Year to date figures for the current period ended September 30, 2020	Year to date figures for the previous period ended September 30, 2019	Previous year ended March 31, 2020
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
- Exchange gain/ (loss) on long-term foreign currency loans, derivatives, deferred consideration and intra-group loans	174.14	528.70	(118.30)	702.84	(140.70)	(551.77)
- Write down of inventory and other expenses on account of Ranitidine withdrawal (refer note 7)	-	(84.83)	-	(84.83)	-	(1,131.12)
- Impairment of Goodwill	-	-	(94.90)	-	(94.90)	(94.89)
- Fair valuation gain on acquisition of controlling shares in Fairmed Healthcare	-	25.30	-	25.30	-	-
- Business combination and restructuring expenses	(19.73)	(0.04)	(15.90)	(19.77)	(33.10)	(42.60)
-Unwinding/ cancellation of gross obligations and contingent consideration (refer note 9)	(23.08)	(19.95)	1,063.46	(43.03)	1,036.60	1,043.58
Total	131.33	449.18	834.36	580.51	767.90	(776.80)

- 9 During the previous year, the Group has cancelled the obligation under the put option to acquire non-controlling interest (49%) of Universal Corporation Limited, Kenya. Consequently, the gross obligation liability accrued at the time of acquisition under the aforesaid put option(including subsequent unwinding) amounting to Rs. 1,092.9 million has been reversed to the Statement of Profit and Loss under exceptional items.



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020**

10 In March 2020, the World Health Organisation declared COVID-19 to be a pandemic. The Group has adopted measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption. The Group has considered available internal and external information while finalizing various estimates in relation to its financial results upto the date of approval of the financial results by the Board of Directors. The actual impact of the global health pandemic may be different from that which has been estimated, as the COVID -19 situation evolves in India and globally. The Group will continue to closely monitor any material changes to future economic conditions.
As of 30 September 2020, the Group's current liabilities exceed its current assets and it has provided certain guarantees in relation to the borrowings of its Associates. However, the Group, based on the fact that it has generated positive operating cash flows in the current period and expects to continue in future periods and its ability to raise new financing facilities / replace existing facilities, believes it will be able to continue to generate sufficient cash to meet its obligations as they fall due.

11 Information on Standalone Results : -

Particulars	Rs. in Million					
	3 Months ended September 30, 2020	Preceding 3 Months ended June 30, 2020	Corresponding 3 Months ended in the previous year September 30, 2019	Year to date figures for the current period ended September 30, 2020	Year to date figures for the pervious period ended September 30, 2019	Previous year ended March 31, 2020
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Total Revenue from continuing operations	4,228.69	4,246.71	4,576.05	8,475.40	9,232.15	17,743.13
Profit before tax from continuing operations	191.97	61.40	582.18	253.37	885.56	1,518.58
Profit after tax from continuing operations	136.77	41.63	469.99	178.40	716.78	1,116.99
Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
Profit/(loss) after tax from discontinued operations	-	-	-	-	-	-

12 The Group's operations for the current and previous year relate only to the "Pharmaceutical business" and accordingly no separate disclosure for business segments is being provided.

13 Previous period figures have been regrouped to conform with the classification adopted in these financial results.

For and on behalf of the Board

**Dr. R Ananthanarayanan
CEO & Managing Director**

Bengaluru, October 29, 2020